Veru gains on positive data for respiratory disease drug in animal study

Veru

04/04/2023 14:02

** Shares of drug developer Veru Inc  VERU.O  rise 13.2% to
$1.29 premarket
    ** Co says its experimental drug to treat influenza-induced
Acute Respiratory Distress Syndrome (ARDS) significantly reduced
lung inflammation in a preclinical animal study   
    ** ARDS is a life-threatening lung injury that allows fluid
to leak into the lungs
    ** VERU plans to initiate a late-stage study of the drug,
sabizabulin, in influenza patients at high risk for ARDS
    ** Expedited meeting granted by U.S. FDA this month for
late-stage confirmatory study in hospitalized COVID-19 patients
at high risk for ARDS - VERU
    ** As of last close, stock down ~78% this year

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))